New offices at leading science hub support the Company’s rapid growth following recent investment
New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA
Cambridge, UK, 21 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth.
Sphere Fluidics recently closed a $4.8 million USD (£3.7 million) funding round, enabling it to hire 10 new staff to expand commercial capabilities and facilitate service and support for its Cyto-Mine® Single Cell Analysis System. Sphere Fluidics sales, marketing, finance and operations teams join the specialist skills pool at Granta Park, one of the UK’s leading life-science research parks, positioned within the Cambridge Science Cluster, taking 1,038sq. ft in the McClintock Building. The Park is home to over 2,500 people and multiple organizations, placing the Company in close proximity to high-quality research and commercialization activity, and opening up the opportunity for further collaborations with potential partners, researchers and suppliers based on the campus.
Sphere Fluidics’ new facilities at Granta Park are in addition to its offices at Babraham Research Campus, Cambridgeshire, UK and Monmouth Junction, New Jersey, USA. The Company also has an established network of international distributors in Japan, France, China, Switzerland, Germany, Austria, Benelux, Australia, Scandinavia and Korea.
Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Recent investment has enabled Sphere Fluidics to accelerate its plans to expand commercial and scientific activities and we are now raising further funding to invest in more new hires and increase our presence in not only the UK but also, the US. It is vital that we are positioned in locations with a flexible and innovative network and look forward to joining the collaborative culture at Granta Park to support these growth projections.”
For further information please contact:
Dr Frank Craig, CEO
Tel: +44 (0)1223 628890
Dr Michelle Ricketts
Tel: +44 (0)7789 053885
About Sphere Fluidics www.spherefluidics.com
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development.
Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology.
Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.
Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.
About Granta Park www.grantapark.co.uk
Granta Park is Cambridge’s leading life-science research park and extends to 120 acres in total. It is a low-density research park, located at the heart of Europe’s strongest and most dynamic cluster of life science and technology-based companies.
Many of these companies were founded to commercialise research that was spun out of the UK’s top-ranked University of Cambridge which is located six miles away. The Park, with planning consent, has been developed exclusively for high-tech companies involved in research and development. Work on the green-field site for Granta Park commenced in 1998 and since that time has grown to 1 million square feet of laboratory and office space with 2,500 people working on the park each day.0